Literature DB >> 8621235

Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs.

I Preuss1, R Thust, B Kaina.   

Abstract

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) removes alkyl groups from the O6 position of guanine in DNA and thus may protect cells against genotoxic effects of agents inducing this lesion. To analyze quantitatively the level of protection mediated by MGMT against antineoplastic drugs, we determined the cytotoxic and recombinogenic (sister-chromatid exchange inducing) effects of various chemotherapeutic agents in a pair of isogenic Chinese hamster cell lines deficient and proficient for MGMT, generated upon transfection with human MGMT cDNA. Furthermore, we compared the responses of the human cell lines HeLa MR (MGMT deficient) and HeLa S3 (MGMT proficient) to the various agents. It is shown that: (1) MGMT proficient cells are resistant in cell killing to the methylating drug streptozotocin and all the chloroethylating nitrosoureas tested. There was a marked agent specificity in protection. The level of resistance provoked by MGMT increased in the order BCNU < CCNU < ACNU < HeCNU < streptozotocin. (2) MGMT did not protect cells against killing induced by chlorambucil, cisplatin, melphalan, activated cyclophosphamide (malosfamide) and activated ifosfamide (4-hydroperoxy-ifosfamide). (3) MGMT caused protection against the recombinogenic effect of all nitrosoureas tested. The lowest level of protection was again observed for BCNU, followed by CCNU, ACNU < HeCNU < streptozotocin. (4) MGMT proficient cells did not exhibit resistance in SCE induction towards cyclophosphamide (activated by microsomes), 4-hydroperoxy-ifosfamide, mafosfamide, chlorambucil and melphalan. Some protection was afforded, however, against cisplatin (and transplatin). This effect was abolished by pretreatment of cells with O6-benzylguanine, which depletes MGMT, indicating that some lesion(s) induced by cisplatin giving rise to SCEs can be repaired by MGMT. Taken together, these results indicate that streptozotocin, HeCNU and ACNU are more selective than CCNU and BCNU in killing MGMT deficient cells, and that in the cases of cyclophosphamide, ifosfamide, chlorambucil, cisplatin and melphalan MGMT is not involved in mediating cytotoxic drug resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621235     DOI: 10.1002/(SICI)1097-0215(19960208)65:4<506::AID-IJC19>3.0.CO;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.

Authors:  Yugo Kishida; Atsushi Natsume; Hiroshi Toda; Yuki Toi; Kazuya Motomura; Hiroko Koyama; Keiji Matsuda; Osamu Nakayama; Makoto Sato; Masaaki Suzuki; Yutaka Kondo; Toshihiko Wakabayashi
Journal:  Tumour Biol       Date:  2012-01-26

Review 2.  Temozolomide dosing regimens for glioma patients.

Authors:  Herwig M Strik; Christine Marosi; Bernd Kaina; Bart Neyns
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

3.  Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.

Authors:  Seema Gupta; Sabapathi Sathishkumar; Mansoor M Ahmed
Journal:  Pancreatology       Date:  2010-10-29       Impact factor: 3.996

4.  Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.

Authors:  Wen-bin Zhang; Zhuo Wang; Fei Shu; Yong-hua Jin; Hong-yi Liu; Qiu-juan Wang; Yong Yang
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

Review 5.  Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Authors:  Bernd Kaina; Geoffrey P Margison; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

6.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

7.  Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards.

Authors:  Rachel Loeber; Erin Michaelson; Qingming Fang; Colin Campbell; Anthony E Pegg; Natalia Tretyakova
Journal:  Chem Res Toxicol       Date:  2008-02-14       Impact factor: 3.739

8.  Selection of chemotherapy for glioblastoma expressing O(6)-methylguanine-DNA methyltransferase.

Authors:  Yasuo Iwadate; Tomoo Matsutani; Yuzo Hasegawa; Natsuki Shinozaki; Takashi Oide; Toru Tanizawa; Yukio Nakatani; Naokatsu Saeki; Shuichi Fujimoto
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

9.  Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.

Authors:  Johannes E A Wolff; Su Berrak; Susannah E Koontz Webb; Ming Zhang
Journal:  J Neurooncol       Date:  2008-02-06       Impact factor: 4.130

10.  Drug resistance and DNA repair in leukaemia.

Authors:  M R Müller; J Thomale; M F Rajewsky; S Seeber
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.